Top 3 Health Care Stocks That May Keep You Up At Night This Month
Thermo Fisher, Moderna and Agilent show overbought RSI readings above 70, warning momentum-focused investors of potential near-term weakness.
Stocks · News reference
Moderna shares are trading higher. The company announced three abstracts on its mRNA-based individualized neoantigen therapy intismeran autogene have been accepted for presentation at the ESMO Congress 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
Biotech companies are increasingly directing capital toward oncology therapeutics, with over $3.9 billion of venture capital flowing into cancer and immunology drug developers in H1 2026. The global oncology drugs market is projected to grow from $256.5 billion in 2025 to nearly $700 billion by 2034, prompting investors to consider biotech ETFs for diversified exposure to this growth opportunity rather than individual stocks.
Moderna Stock Is Soaring: What's Going On?
Moderna shares are surging Monday. The company announced three intismeran autogene abstracts were accepted for presentation at ESMO Congress.